Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like organic cation (OCT) and multidrug and toxin extrusion (MATE) are involved in...

Full description

Bibliographic Details
Main Authors: Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Andrzej Czyrski, Natalia Kostewicz, Paulina Kaczmarska, Małgorzata Bekier, Joanna Stanisławiak-Rudowicz, Marta Karaźniewicz-Łada, Anna Wolc, Franciszek Główka, Edmund Grześkowiak, Edyta Szałek
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Pharmaceutics
Subjects:
sorafenib
sorafenib N-oxide
atorvastatin
metformin
pharmacokinetics
drug–drug interaction
Online Access:https://www.mdpi.com/1999-4923/12/7/600

Internet

https://www.mdpi.com/1999-4923/12/7/600

Similar Items